Also a good read..from the International Journal of Cancer Research & Therapy.
Of particular note see page 4, Table 2: Response rates for newer acute myelogenous leukemia therapies in development (bisantrene competitors).
That is, the reported response rates for bisantrene in AML (averaging 48% across historical phase 2 trials) are comparable to the best (46% complete response with Clofarabine), or better than, the majority of drugs (24%-34%) currently in development (Table 2).
Ann: June 2018 Quarterly Report, page-5
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
